Abstract
Purpose
Leptomycin B (LMB) and/or its derivatives are considered a novel class of cancer therapeutics through blocking chromosome maintenance region 1, which mediates p53 nuclear export. The objectives of the present study were to first evaluate the cytotoxic effects of LMB on a normal human lung epithelial cell line (BEAS-2B) and three human lung adenocarcinoma cell lines with various p53 status (wild type: A549, mutant: NCI-H522, and null: NCI-H358) and then to identify LMB-induced gene expression alterations in human p53 signaling pathway.
Methods
Cells were treated with 0.01–100 nM LMB or 0.1% ethanol (vehicle control) for 4–72 h. Gene expression analyses using gene array for 84 genes involved in p53-mediated signaling pathways were performed in A549 and NCI-H358 after treatment with 20 nM LMB or vehicle control for 24 h.
Results
Cytotoxic results from MTS assays revealed a significant dose- and time-dependent effect of LMB on all cell lines. However, this effect was more pronounced in cancer cells than in normal cells, and cancer cells with p53 wild type tended to be less sensitive than those with p53 mutant or null. A total of 23 genes, predominantly involved in apoptosis and cell cycle/proliferation, were significantly altered in A549 after LMB treatment, while no strong modulating effects were observed in NCI-H358. The protein expression of two selected genes, p21 and survivin, was further confirmed by Western blots.
Conclusion
Our results suggest that LMB has anti-cancer potential and provides a new regimen of individualized therapy for lung cancer treatment.
Similar content being viewed by others
References
Garcia M, Jemal A, Ward EM et al (2007) Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta
Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249
Hecht SS (2005) Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis 26:1488–1492
Devesa SS, Bray F, Vizcaino AP et al (2005) International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117:294–299
American Cancer Society (2009) Cancer Facts & Figures 2009. American Cancer Society, Atlanta
Bunn PA Jr, Thatcher N (2008) Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13 Suppl 1:37–46
Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1:5–13
Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331
Greenblatt MS, Bennett WP, Hollstein M et al (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878
Gao WM, Mady HH, Yu GY et al (2003) Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer 40:141–150
Bennett WP, Hussain SP, Vahakangas KH et al (1999) Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187:8–18
Foo RS, Nam YJ, Ostreicher MJ et al (2007) Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci USA 104:20826–20831
Fried H, Kutay U (2003) Nucleocytoplasmic transport: taking an inventory. Cell Mol Life Sci 60:1659–1688
Mutka SC, Yang WQ, Dong SD et al (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69:510–517
Kau TR, Way JC, Silver PA (2004) Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4:106–117
van der Watt PJ, Maske CP, Hendricks DT et al (2008) The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124:1829–1840
Shen A, Wang Y, Zhao Y et al (2009) Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65:153–159 discussion 159–160
Huang WY, Yue L, Qiu WS et al (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32:E315
Komiyama K, Okada K, Tomisaka S et al (1985) Antitumor activity of leptomycin B. J Antibiot (Tokyo) 38:427–429
Yoshida M, Nishikawa M, Nishi K et al (1990) Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp Cell Res 187:150–156
Roberts BJ, Hamelehle KL, Sebolt JS et al (1986) In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114, 721). Cancer Chemother Pharmacol 16:95–101
Macara IG (2001) Transport into and out of the nucleus. Microbiol Mol Biol Rev 65:570–594
Cook A, Bono F, Jinek M et al (2007) Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 76:647–671
Hoshino I, Matsubara H, Komatsu A et al (2008) Combined effects of p53 gene therapy and leptomycin B in human esophageal squamous cell carcinoma. Oncology 75:113–119
Freedman DA, Levine AJ (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18:7288–7293
Lecane PS, Kiviharju TM, Sellers RG et al (2003) Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate 54:258–267
Caglieri A, Goldoni M, De Palma G et al (2008) Exposure to low levels of hexavalent chromium: target doses and comparative effects on two human pulmonary cell lines. Acta Biomed 79 Suppl 1:104–115
Smart P, Lane EB, Lane DP et al (1999) Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18:7378–7386
Yang B, Eshleman JR, Berger NA et al (1996) Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2:1649–1657
Giannakakou P, Poy G, Zhan Z et al (2000) Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19:3078–3085
Lowe SW, Schmitt EM, Smith SW et al (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847–849
Clarke AR, Purdie CA, Harrison DJ et al (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849–852
Lowe SW, Ruley HE, Jacks T et al (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967
Shaw P, Bovey R, Tardy S et al (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495–4499
Kuerbitz SJ, Plunkett BS, Walsh WV et al (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491–7495
Fan S, el-Deiry WS, Bae I et al (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824–5830
Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72–79
Zhang CC, Yang JM, White E et al (1998) The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16:1617–1624
Yu X, Robinson JF, Gribble E et al (2008) Gene expression profiling analysis reveals arsenic-induced cell cycle arrest and apoptosis in p53-proficient and p53-deficient cells through differential gene pathways. Toxicol Appl Pharmacol 233:389–403
Wang XW (1999) Role of p53 and apoptosis in carcinogenesis. Anticancer Res 19:4759–4771
Fischer M, Skowron M, Berthold F (2005) Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 7:89–96
Gaj S, Eijssen L, Mensink RP et al (2008) Validating nutrient-related gene expression changes from microarrays using RT(2) PCR-arrays. Genes Nutr 3:153–157
Shimo A, Nishidate T, Ohta T et al (2007) Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci 98:174–181
Le Gac G, Esteve PO, Ferec C et al (2006) DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1. J Biol Chem 281:24161–24170
Mirza A, McGuirk M, Hockenberry TN et al (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613–2622
Tu SP, Jiang XH, Lin MC et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724–7732
Knauer SK, Kramer OH, Knosel T et al (2007) Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 21:207–216
Saxena A, Rorie CJ, Dimitrova D et al (2006) Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene 25:7274–7288
Wawrzynow B, Zylicz A, Wallace M et al (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chem 282:32603–32612
Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054–1072
Lee YS, Wan J, Kim BJ et al (2006) Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen. J Pharmacol Exp Ther 317:202–208
Menendez S, Higgins M, Berkson RG et al (2003) Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. Br J Cancer 88:636–643
Milutinovic S, Knox JD, Szyf M (2000) DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21 (WAF1/CIP1/sdi1). J Biol Chem 275:6353–6359
Tan HH, Porter AG (2009) p21(WAF1) negatively regulates DNMT1 expression in mammalian cells. Biochem Biophys Res Commun 382:171–176
Duriez C, Moyret-Lalle C, Falette N et al (2004) BTG2, its family and its tutor. Bull Cancer 91:E242–E253
Hay N (2008) p53 strikes mTORC1 by employing sestrins. Cell Metab 8:184–185
Cooper WA, Kohonen-Corish MR, Zhuang L et al (2008) Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 113:135–142
Jang BC, Paik JH, Jeong HY et al (2004) Leptomycin B-induced apoptosis is mediated through caspase activation and down-regulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells. Biochem Pharmacol 68:263–274
Vigneri P, Wang JY (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7:228–234
Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg Effect” and a pivotal target for effective therapy. Semin Cancer Biol 19:17–24
Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777–4786
Pelaez R, Herrero P, Moreno F (2009) Nuclear export of the yeast hexokinase 2 protein requires the Xpo1 (Crm1)-dependent pathway. J Biol Chem 284:20548–20555
Kim W, Yoon JH, Jeong JM et al (2007) Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 6:2554–2562
Bihl M, Tamm M, Nauck M et al (1998) Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19:606–612
Regis G, Icardi L, Conti L et al (2009) IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia 23:2102–2108
Moodley YP, Misso NL, Scaffidi AK et al (2003) Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 29:490–498
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Shao, C., Lu, C., Chen, L. et al. p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol 67, 1369–1380 (2011). https://doi.org/10.1007/s00280-010-1434-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-010-1434-6